Epigenetic modifications and emerging therapeutic targets in cardiovascular aging and diseases.

Yurou Qiu, Qing Xu, Peichen Xie, Chenshuang He, Qiuchan Li, Xin Yao, Yang Mao, Xiaoqian Wu, Tiejun Zhang

GMU-GIBH Joint School of Life Sciences, Department of Cardiology, Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, the Second Affiliated Hospital, The Guangdong-Hong Kong-Macao Joint Laboratory for Cell Fate Regulation and Diseases, State Key Laboratory of Respiratory Disease, The Sixth School of Clinical Medicine, the Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Guangdong Pharmaceutical University, Guangzhou, Guangdong, PR China. · pubmed

Paper

Abstract

The complex mechanisms underlying the development of cardiovascular diseases remain not fully elucidated. Epigenetics, which modulates gene expression without DNA sequence changes, is shedding light on these mechanisms and their heritable effects. This review focus on epigenetic regulation in cardiovascular aging and diseases, detailing specific epigenetic enzymes such as DNA methyltransferases (DNMTs), histone acetyltransferases (HATs), and histone deacetylases (HDACs), which serve as writers or erasers that modify the epigenetic landscape. We also discuss the readers of these modifications, such as the 5-methylcytosine binding domain proteins, and the erasers ten-eleven translocation (TET) proteins. The emerging role of RNA methylation, particularly N6-methyladenosine (m

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

The paper discusses epigenetic modifications in the context of cardiovascular aging and diseases, which are relevant to understanding the biological mechanisms of aging. However, it primarily focuses on the regulation of gene expression and potential therapeutic targets rather than addressing the root causes of aging or lifespan extension. While it provides solid insights into the role of epigenetics in cardiovascular health, its impact is limited as it does not propose significant breakthroughs or transformative approaches to longevity research.

Author of this paper? Send a correction.